Kyverna Therapeutics, Inc. Payments to Acquire Marketable Securities
Kyverna Therapeutics, Inc. (KYTX) reported Payments to Acquire Marketable Securities of $147.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- Kyverna Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $31.92M, a 66.30% decline year-over-year.
- Kyverna Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $115.90M, a 42.87% increase year-over-year.
- Kyverna Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $115.95M, a 8.88% decline year-over-year.
- Kyverna Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $72.82M, a 47.05% decline year-over-year.
- Kyverna Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $364.62M, a 25.59% decline from fiscal 2024.
- Kyverna Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $490.00M, a 793.39% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $54.85M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $147.82M 10-Q · filed 2026-08-11 | $263.77M derived: sum of 3 quarters · filed 2026-08-11 | $336.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $115.90M 10-Q · filed 2026-05-12 | $231.85M derived: sum of 2 quarters · filed 2026-05-12 | $304.67M derived: sum of 3 quarters · filed 2026-05-12 | $399.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $115.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $188.77M derived: sum of 2 quarters · filed 2026-03-26 | $283.50M derived: sum of 3 quarters · filed 2026-08-11 | $364.62M 10-K · filed 2026-03-26 |
| 2025-09-30 | $72.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $167.55M derived: sum of 2 quarters · filed 2026-08-11 | $248.67M 10-Q · filed 2025-11-12 | $375.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $94.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $175.85M 10-Q · filed 2026-08-11 | $303.10M derived: sum of 3 quarters · filed 2026-08-11 | $440.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $81.12M 10-Q · filed 2026-05-12 | $208.37M derived: sum of 2 quarters · filed 2026-05-12 | $345.89M derived: sum of 3 quarters · filed 2026-05-12 | $425.78M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $127.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $264.77M derived: sum of 2 quarters · filed 2026-03-26 | $344.66M derived: sum of 3 quarters · filed 2026-03-26 | $490.00M 10-K · filed 2026-03-26 |
| 2024-09-30 | $137.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $217.41M derived: sum of 2 quarters · filed 2025-11-12 | $362.75M 10-Q · filed 2025-11-12 | $363.74M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $79.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $225.23M 10-Q · filed 2025-08-12 | $226.21M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $145.34M 10-Q · filed 2025-05-13 | $146.32M derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $54.85M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $53.86M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |